BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Breakthrough Medical and Pharmaceutical Funding Awarded to Consortium That Partners Avita Medical With 20 Other Organisations Across Australia

  Regenerative skin company Avita Medical is delighted to be part of Accelerating Australia, a consortium that will inject up to $2 million into a breakthrough innovation project designed to commercialise big ideas.

  October 26, 2017

   · 

  5 min read
• Biotech Beach

  Lin BioScience Receives U.S. FDA Orphan Drug Status for LBS-008 for the Treatment of Stargardt Disease

  Lin BioScience announced today that the FDA has granted orphan drug designation to LBS-008, a first-in-class oral therapy for the treatment of Stargardt Disease.

  October 26, 2017

   · 

  2 min read
• Business

  Recordati: Very Good Results In The First Nine Months 2017. Continued Growth In Sales +11.8%, Operating Income +21.8%, Net Income +20.6%. Interim Dividend € 0.42 (+20%)

  These financial statements will be available today at the company’s offices and on the company’s website.

  October 26, 2017

   · 

  12 min read
• Business

  Loxo Oncology to Announce Third Quarter 2017 Financial Results and Host Conference Call

  Loxo Oncology management will host a conference call to discuss these financial results, in addition to recent updates on development and corporate activities.

  October 26, 2017

   · 

  1 min read
• Drug Development

  MediciNova Announces Positive Top-Line Results from the SPRINT-MS Phase IIb Trial of MN-166 (ibudilast) in Progressive MS: Achieved Both Primary Endpoints including a Significant Reduction in Whole Brain Atrophy and Safety and Tolerability

  The study was conducted by the NeuroNEXT network with funding from the NIH National Institute of Neurological Diseases and Stroke, the National Multiple Sclerosis Society, and MediciNova.

  October 26, 2017

   · 

  9 min read
• Business

  Integra LifeSciences Reports Third Quarter 2017 Financial Results

  Total revenues for the third quarter were $278.8 million, reflecting an increase of $28.5 million, or 11.4%, over the third quarter of 2016.

  October 26, 2017

   · 

  21 min read
• Business

  Sonoma Pharmaceuticals Announces Fiscal Second Quarter 2018 Financial Results and Conference Call

  The earnings release will be followed by a conference call at 1:30 p.m. PST on November 9, 2017, to discuss fiscal second quarter results.

  October 26, 2017

   · 

  1 min read
• Business

  Catalyst Biosciences Announces the Appointment of Industry Veteran Andrea Hunt to its Board of Directors

  Ms. Hunt was most recently vice president, New Product Gene Therapy, Neuroscience, Oncology, Ophthalmology at Shire.

  October 26, 2017

   · 

  3 min read
• Drug Development

  Atara Biotherapeutics Receives Rare Pediatric Disease Designation From FDA for ATA230 for Treatment of Congenital Cytomegalovirus (CMV) Infection

  The FDA grants Rare Pediatric Disease designation to drugs or biologics intended to treat serious or life-threatening rare diseases that primarily affect individuals aged from birth to 18 years and fewer than 200,000 persons in the U.S.

  October 26, 2017

   · 

  6 min read
• 

  Drug Development

  Kitov Pharma Surges as Lead Drug Hits Goals in Phase III Test

  Kitov announced today that its randomized double-blind, placebo-controlled renal function clinical trial for its lead drug candidate, KIT-302, successfully met its primary efficacy endpoint.

  October 26, 2017

   · 

  7 min read